Taiho Pharmaceutical Co Ltd-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Taiho Pharmaceutical Co Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8012235
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月14日
◆ページ数:38
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:日本
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Taiho Pharmaceutical Co Ltd (Taiho), a subsidiary of Otsuka Group focuses on the development, production and marketing of pharmaceutical products in the fields of cancer, allergy, immunology, urology and others. Its product portfolio includes pharmaceutical products such as anti-allergic agents, anti-tumor agents, H2 receptor antagonists, antibiotics and medical devices; and consumer health products such as vitamin tonic, herbal digestive medicine, topical analgesics, antifungal cream, herbal medicine powder, and others. Taiho has production facilities in Tokushima, Saitama, Okayama, Kitajima and Inuyama. It operates through its subsidiaries in Japan, China, Singapore, the UK and the US. Taiho is headquartered in Tokyo, Japan.

Taiho Pharmaceutical Co Ltd – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Taiho Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Taiho Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Taiho Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Taiho Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Taiho Pharmaceutical Co Ltd, Medical Devices Deals, 2011 to YTD 2017 9
Taiho Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Taiho Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
Taiho Pharma Acquires Fermentation Research-Related Assets from Astellas Pharma 12
Venture Financing 13
Arcus Biosciences Raises USD107 Million in Series C Financing 13
Harpoon Therapeutics Raises USD45 Million in series B Financing 15
Arcus Biosciences Raises USD70 Million in Series B Financing 16
Partnerships 17
X-Chem Enters into Agreement with Taiho Pharma 17
Merck Enters into Co-Promotion Agreement with Taiho Pharma for Pembrolizumab 18
Taiho Pharma Enters into Co-Marketing Agreement with Meiji Seika Pharma 19
Response Genetics Extends Agreement With Taiho Pharma For Molecular Markers 20
Taiho Pharma Enters Into Development Agreement With Nordic Group For Teysuno 21
MSD Enters Into Co-Marketing Agreement With Taiho Pharma For Vorinostat 22
Licensing Agreements 23
Taiho Pharma Enters into Option and Licensing Agreement with Arcus Biosciences 23
Taiho Pharma Enters into Licensing Agreement with Servier 24
Taiho Pharma Enters Into Licensing Agreement With Faes Farma For Bilastine 25
Taiho Pharma Extends Licensing Agreement With Helsinn Healthcare 27
Taiho Pharmaceutical Co Ltd – Key Competitors 29
Taiho Pharmaceutical Co Ltd – Key Employees 30
Taiho Pharmaceutical Co Ltd – Locations And Subsidiaries 31
Head Office 31
Other Locations & Subsidiaries 31
Recent Developments 32
Strategy And Business Planning 32
Jun 02, 2017: Taiho Pharmaceutical to Construct Facility for Production of Highly Potent Pharmaceutical Ingredients 32
Mar 07, 2017: Taiho Pharmaceutical Announces Expansion into Canada 33
May 10, 2016: Taiho Pharmaceutical establishes Taiho Ventures to support oncology biotech start-ups 34
Legal and Regulatory 35
May 31, 2016: Otsuka Holdings Announces New, Additional Certification Under “ISO 22301”, the International Standard for Business Continuity Management 35
Product News 36
Oct 05, 2017: Taiho Pharmaceutical Releases Pitas Sore Throat Troche in Japan on October 5A Sticker-type Troche to be Placed on the Roof of the Mouth That is Helpful in Business Meetings 36
Feb 07, 2017: Taiho Pharmaceutical Releases Pure Quick S Ointment, a New Mini Size Steroid Product 37
Appendix 38
Methodology 38
About GlobalData 38
Contact Us 38
Disclaimer 38

List of Tables
Taiho Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Taiho Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Taiho Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Taiho Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Taiho Pharmaceutical Co Ltd, Deals By Therapy Area, 2011 to YTD 2017 8
Taiho Pharmaceutical Co Ltd, Medical Devices Deals, 2011 to YTD 2017 9
Taiho Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Taiho Pharma Acquires Fermentation Research-Related Assets from Astellas Pharma 12
Arcus Biosciences Raises USD107 Million in Series C Financing 13
Harpoon Therapeutics Raises USD45 Million in series B Financing 15
Arcus Biosciences Raises USD70 Million in Series B Financing 16
X-Chem Enters into Agreement with Taiho Pharma 17
Merck Enters into Co-Promotion Agreement with Taiho Pharma for Pembrolizumab 18
Taiho Pharma Enters into Co-Marketing Agreement with Meiji Seika Pharma 19
Response Genetics Extends Agreement With Taiho Pharma For Molecular Markers 20
Taiho Pharma Enters Into Development Agreement With Nordic Group For Teysuno 21
MSD Enters Into Co-Marketing Agreement With Taiho Pharma For Vorinostat 22
Taiho Pharma Enters into Option and Licensing Agreement with Arcus Biosciences 23
Taiho Pharma Enters into Licensing Agreement with Servier 24
Taiho Pharma Enters Into Licensing Agreement With Faes Farma For Bilastine 25
Taiho Pharma Extends Licensing Agreement With Helsinn Healthcare 27
Taiho Pharmaceutical Co Ltd, Key Competitors 29
Taiho Pharmaceutical Co Ltd, Key Employees 30
Taiho Pharmaceutical Co Ltd, Subsidiaries 31

★海外企業調査レポート[Taiho Pharmaceutical Co Ltd-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Genedrive Plc (GDR):企業の財務・戦略的SWOT分析
    Genedrive Plc (GDR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Suda Pharmaceuticals Ltd (SUD):企業の財務・戦略的SWOT分析
    Summary Suda Pharmaceuticals Ltd (Suda Pharmaceuticals), formerly Suda Ltd is a drug delivery company that offers oro-mucosal administration solutions. The company offers products such as SUD-001, SUD-002, SUD-003, SUD-004 and SUD-005, artimist, and zolpimist. Its artimist is a sub-lingual spray for …
  • JM Financial Private Wealth Group:企業の戦略・SWOT・財務情報
    JM Financial Private Wealth Group - Strategy, SWOT and Corporate Finance Report Summary JM Financial Private Wealth Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • PT Rekayasa Industri:企業の戦略的SWOT分析
    PT Rekayasa Industri - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Tokyo Seimitsu Co., Ltd. (7729):企業の財務・戦略的SWOT分析
    Tokyo Seimitsu Co., Ltd. (7729) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Monsanto Co (MON):企業の財務・戦略的SWOT分析
    Monsanto Co (MON) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Arsenal Holdings plc:企業の戦略的SWOT分析
    Arsenal Holdings plc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Immunomic Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Immunomic Therapeutics Inc (ITI) is a clinical-stage biotechnology company that develops patented lysosomal-associated membrane protein or lamp technology based nucleic acid immunotherapy platforms. The company’s vaccines utilize the body’s natural biochemistry to develop immune response inc …
  • Octapharma AG:企業の戦略・SWOT・財務情報
    Octapharma AG - Strategy, SWOT and Corporate Finance Report Summary Octapharma AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • JX Nippon Oil & Energy Corporation-エネルギー分野:企業M&A・提携分析
    Summary JX Nippon Oil & Energy Corporation (JXNOE) is a downstream refining company. The company refines and markets petroleum and petrochemical products. Its products include petrochemicals, lubricants, optical films, greases, fluids, engine oils, composites, Panaferd-AX, Tow PREPREG, sheet pallet …
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (1349):企業の財務・戦略的SWOT分析
    Summary Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (FDZJ), a subsidiary of Shanghai Pharmaceutical Co Ltd, is a bio-pharmaceutical company that develops, manufactures and markets genetic engineering drugs. The company offers bio-pharmaceutical products in the field of genetic engineering, p …
  • Hansard Global plc:企業の戦略・SWOT・財務情報
    Hansard Global plc - Strategy, SWOT and Corporate Finance Report Summary Hansard Global plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • APA Group:企業のM&A・事業提携・投資動向
    APA Group - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's APA Group Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capita …
  • Bio-Rad Laboratories Inc (BIO)-製薬・医療分野:企業M&A・提携分析
    Summary Bio-Rad Laboratories Inc (Bio-Rad) develops and manufactures specialty chemicals for use in biochemical, pharmaceutical and other life science research applications. The company offers a comprehensive range of reagents, apparatus, laboratory instruments, test systems, informatics systems, te …
  • Groupe Bruxelles Lambert SA (GBLB):企業の財務・戦略的SWOT分析
    Groupe Bruxelles Lambert SA (GBLB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • St. James’S Place Plc:企業の戦略・SWOT・財務分析
    St. James'S Place Plc - Strategy, SWOT and Corporate Finance Report Summary St. James'S Place Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • DBV Technologies SA (DBV):製薬・医療:M&Aディール及び事業提携情報
    Summary DBV Technologies SA (DBV) is a biopharmaceutical company that develops products for the diagnosis and treatment of food and pediatric allergies. The company develops and markets non-invasive epicutaneous delivery technology and products for healthcare markets. Its viaskin technology platform …
  • BioRestorative Therapies Inc (BRTX):企業の財務・戦略的SWOT分析
    Summary BioRestorative Therapies Inc (BRT), formerly Stem Cell Assurance Inc is a developer of therapeutic products and medical therapies. The company performs stem cell programs which include brtxDISC and ThermoStem. brtxDISC,a lead therapeutic product, is designed to offer a non-surgical treatment …
  • SIGA Technologies Inc (SIGA):企業の財務・戦略的SWOT分析
    Summary SIGA Technologies Inc (SIGA) is a health security service provider. The company develops and commercialise solutions for serious unmet medical needs and bio threats. It offers antiviral drug to treat smallpox disease. SIGA offers product such as TPOXX. The company’s Tecovirimat is combined w …
  • Shriram Transport Finance Company Ltd.:企業のM&A・事業提携・投資動向
    Shriram Transport Finance Company Ltd. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Shriram Transport Finance Company Ltd. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed repo …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆